文献速递MDS 与骨髓增殖性肿瘤

基于临床与基因组数据的骨髓增生异常综合征个体化预后预测模型

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
PubMed 文献 · J Clin Oncol · 2021-08-18

该研究纳入1471例骨髓增生异常综合征(MDS)患者作为训练队列,利用机器学习中的随机生存算法构建预后模型,并在465例独立外部队列、前瞻性临床试验队列、配对样本队列及造血干细胞移植队列中验证。模型整合染色体核型、血小板、血红蛋白、骨髓原始细胞比例、年龄、7个离散基因突变及突变数目等变量,预测总生存和无白血病生存,其区分度优于现有预后模型。

要点

  • 基于临床与基因组数据的个体化模型在MDS中优于现有预后模型。
  • 模型可动态预测患者不同时间点的生存和白血病转化概率。
  • 模型能上调或下调患者风险分类,使其归入更合适的风险组。

核心结论

  • 基于临床和基因组数据的个体化预测模型在MDS中优于现有预后模型。
  • 新模型是动态的,可预测给定患者在不同时间点独特的生存和白血病转化概率。
  • 模型可将患者上调或下调至更合适的风险类别。

研究设计与样本

  • 训练队列共1471例具有全面临床和分子注释的MDS患者,采用机器学习技术分析。
  • 使用随机生存算法构建预后模型,并在外部队列中验证。
  • 验证队列包括465例独立外部队列、前瞻性临床试验中的MDS患者队列、病程不同时间点配对样本队列及接受造血干细胞移植的患者队列。
  • 采用一致性指数(c指数)评估模型与其他已建立模型的准确性。

主要发现

  • 训练队列中位年龄为71岁,常见突变基因为SF3B1、TET2和ASXL1。
  • 算法识别出染色体核型、血小板、血红蛋白水平、骨髓原始细胞百分比、年龄、其他临床变量、7个离散基因突变及突变数目对总生存和无白血病生存有预后影响。

关键数值与推荐

  • 训练队列中位年龄为71岁。
  • 常见突变基因包括SF3B1、TET2和ASXL1。
  • 对总生存和无白血病生存有预后影响的变量包括染色体核型、血小板、血红蛋白水平、骨髓原始细胞百分比、年龄、其他临床变量、7个离散基因突变及突变数目。

临床怎么用

  • 该模型可用于MDS患者的个体化风险分层,动态预测不同时间点的生存和白血病转化概率。
  • 模型可上调或下调患者风险分类,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with myelodysplastic syndromes (MDS) have a survival that can range from months to decades. Prognostic systems that incorporate advanced analytics of clinical, pathologic, and molecular data have the potential to more accurately and dynamically predict survival in patients receiving various therapies. METHODS: A total of 1,471 MDS patients with comprehensively annotated clinical and molecular data were included in a training cohort and analyzed using machine learning techniques. A random survival algorithm was used to build a prognostic model, which was then validated in external cohorts. The accuracy of the proposed model, compared with other established models, was assessed using a concordance (c)index. RESULTS: The median age for the training cohort was 71 years. Commonly mutated genes included SF3B1, TET2, and ASXL1. The algorithm identified chromosomal karyotype, platelet, hemoglobin levels, bone marrow blast percentage, age, other clinical variables, seven discrete gene mutations, and mutation number as having prognostic impact on overall and leukemia-free survivals. The model was validated in an independent external cohort of 465 patients, a cohort of patients with MDS treated in a prospective clinical trial, a cohort of patients with paired samples at different time points during the disease course, and a cohort of patients who underwent hematopoietic stem-cell transplantation. CONCLUSION: A personalized prediction model on the basis of clinical and genomic data outperformed established prognostic models in MDS. The new model was dynamic, predicting survival and leukemia transformation probabilities at different time points that are unique for a given patient, and can upstage and downstage patients into more appropriate risk categories.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nazha A, Komrokji R, Meggendorfer M, et al. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021. PMID: 34406850. doi:10.1200/JCO.20.02810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。